Tanfanercept (HL036)
Tanfanercept is the most advanced novel biological approach to suppressing tumor necrosis factor (TNF) that causes inflammation in the body. HanAll is developing tanfanercept as an ophthalmic drug to provide better treatment options to the patients while extending the indications to relevant diseases.
Mechanism of Action
Tumor necrosis factor is a pro-inflammatory cytokine that plays a pivotal role in inflammatory response. Tumor necrosis factor receptor 1 (TNFR1) signaling is known to be pro-inflammatory and the suppression of TNFR1 is crucial for the treatment of autoimmune diseases. Tanfanercept is a molecularly engineered TNFR1 fragment adopting ’Resistein’, an amino acid substitution technique originally developed by HanAll Biopharma. Tanfanercept strongly binds to TNF and exhibits high stability, as it is resistant to enzymatic lysis. In addition, tanfanercept is efficiently distributed across the whole body with local administration owing to its small size (approximately 19 kDa). Based on these characteristics, we expect that tanfanercept will be effective in suppressing inflammatory responses, and improving symptoms of inflammatory eye disease.